UTMD (Utah Medical Products) ROCE %: 8.71% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UTMD Utah Medical Products Inc UTMD
73 GF Score
Price $70.84
GF Value $57.89
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Utah Medical Products ROCE %?

Utah Medical Products UTMD +0.41% 73 ROCE % is 8.71% as of Jun. 2026. GuruFocus rates UTMD with a GF Score™ of 73/100 and a GF Value™ of $57.89 (Modestly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Utah Medical Products's annualized ROCE % for the quarter that ended in Jun. 2026 was 8.71%.

Utah Medical Products  (NAS:UTMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Utah Medical Products ROCE % Related Terms

Utah Medical Products ROCE % Historical Data

* Premium members only.

The historical data trend for Utah Medical Products's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Utah Medical Products ROCE % Chart

Utah Medical Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.18 17.22 13.49 10.90 9.55

Utah Medical Products Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.80 8.79 8.17 9.99 8.71
UTMD
73GF Score
Utah Medical Products Inc UTMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Utah Medical Products ROCE % Calculation

Utah Medical Products's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=11.402/( ( (122.538 - 3.757) + (122.542 - 2.598) )/ 2 )
=11.402/( (118.781+119.944)/ 2 )
=11.402/119.3625
=9.55 %

Utah Medical Products's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=10.596/( ( (124.382 - 3.505) + (124.572 - 2.07) )/ 2 )
=10.596/( ( 120.877 + 122.502 )/ 2 )
=10.596/121.6895
=8.71 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.71% mean?
Utah Medical Products (UTMD) has a ROCE % of 8.71% as of Jun. 2026.
Is Utah Medical Products' ROCE % too high?
Utah Medical Products' current ROCE % is 8.71%. The Medical Devices & Instruments industry median ROCE % is 3.31. Utah Medical Products' value of 8.71% is 163.1% above this industry median. Overall, Utah Medical Products has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' ROCE % compare to EMBC and SMTI?
Utah Medical Products' ROCE % of 8.71% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.31. Utah Medical Products' value of 8.71% is 163.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.31, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current ROCE % of 8.71% is 163.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current ROCE % is 8.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Based on GuruFocus' analysis, Utah Medical Products (UTMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $57.89, compared to a current price of $70.84 — trading 22.4% above its estimated fair value. The current ROCE % is 8.71% and 163.1% above the Medical Devices & Instruments industry median of 3.31. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Utah Medical Products (UTMD), the current ROCE % is 8.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Utah Medical Products (UTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued. The current stock price of $70.84 is trading 22.4% above its estimated GF Value™ of $57.89. GuruFocus considers Utah Medical Products to be Modestly Overvalued.

Key valuation signals for UTMD:

  • ROCE %: 8.71%
  • GF Value™: $57.89 vs. price of $70.84 (22.4% above fair value)
  • GF Score™: 73/100 with 8 warning signs
  • Industry Position: 163.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the UTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Utah Medical Products Business Description

Other Exchanges UTM:Germany
Address 7043 South 300 West, Midvale, UT, USA, 84047
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score

Get the complete analysis for UTMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$70.84
Price
$57.89
GF Value